id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
bam-12937	Moshkani Farahani, Maryam; Nasiri, Alireza; Salari, Mahdi; Shamsedini, Ali	The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up	2024	9	.pdf	application/pdf	5893	285	47	PCSK9, a liver-secreted serine protease, plays a crucial role by regulating LDL cholesterol levels. The BERSON trial design by Lorenzatti et al. (2018) targets patients with type 2 diabetes and dyslipidemia, reflecting a similar ra- tionale for evolocumab in FH patients where statins may be insufficient.27 However, it’s important to acknowledge that our study did not differentiate between HeFH and HoFH subtypes, which might require tailored treatment approaches.	cache/bam-12937.pdf	txt/bam-12937.txt